InvestorsHub Logo
Followers 484
Posts 60827
Boards Moderated 18
Alias Born 09/20/2001

Re: None

Wednesday, 01/27/2021 9:31:38 AM

Wednesday, January 27, 2021 9:31:38 AM

Post# of 7900
$3 secondary...


Free Writing Prospectus - Filing Under Securities Act Rules 163/433 (fwp)
January 27 2021 - 08:39AM
Edgar (US Regulatory)
Alert
Print
Share On Facebook
Free Writing Prospectus dated January 26, 2021

Filed pursuant to Rule 433

Relating to the Preliminary Prospectus Supplement dated

January 26, 2021

Registration Statements Nos. 333-236200 and 333-252451





TransEnterix Increases Previously Announced Bought Deal Offering of Common Stock to $69.25 Million



RESEARCH TRIANGLE PARK, N.C. — (BUSINESS WIRE)—Jan. 26, 2021— TransEnterix, Inc. (NYSE American: TRXC) (“TransEnterix” or the “Company”), a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery, today announced that, due to demand, the underwriter has agreed to increase the size of the previously announced offering and purchase on a firm commitment basis 23,083,333 shares of common stock of the Company at a public offering price of $3.00 per share, less underwriting discounts and commissions. The Company also has granted the underwriter a 30-day option to purchase up to an additional 3,462,499 shares of common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on or about January 29, 2021, subject to customary closing conditions.



H.C. Wainwright & Co. is acting as the sole book-running manager for the offering.



The gross proceeds of the offering are expected to be approximately $69.25 million, prior to deducting underwriting discounts and commissions and estimated offering expenses and excluding the exercise of the underwriter’s option to purchase additional shares. The Company intends to use the net proceeds from this offering for general corporate purposes, including working capital and funding research and development activities.



The shares of common stock are being offered pursuant to an effective registration statement on Form S-3 (File No. 333-236200) that was filed with the U.S. Securities and Exchange Commission (“SEC”) on January 31, 2020 and declared effective on February 10, 2020 and an additional registration statement on Form S-3 filed pursuant to Rule 462(b) and became automatically effective on January 26, 2021. The shares of common stock may be offered only by means of a prospectus. A preliminary prospectus supplement and accompanying prospectus relating to the offering were filed with the SEC and are available on the SEC’s website at www.sec.gov. Electronic copies of the final prospectus supplement and accompanying prospectus relating to the offering, when filed, may be obtained from H.C. Wainwright & Co., LLC, 430 Park Avenue, New York, NY 10022, by email at placements@hcwco.com or by phone at (646) 975-6996.



This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful, prior to registration or qualification under the securities laws of any such state or jurisdiction.


https://ih.advfn.com/stock-market/AMEX/transenterix-TRXC/stock-news/84180786/free-writing-prospectus-filing-under-securities


Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ASXC News